<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893291</url>
  </required_header>
  <id_info>
    <org_study_id>TRANSFORM II</org_study_id>
    <nct_id>NCT04893291</nct_id>
  </id_info>
  <brief_title>Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels</brief_title>
  <acronym>TRANSFORM II</acronym>
  <official_title>Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Ricerca e Innovazione Cardiovascolare ETS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Ricerca e Innovazione Cardiovascolare ETS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicentric, prospective, investigator-driven, open-label, randomized (1:1)&#xD;
      clinical trial to observe and evaluate the efficacy, of Magic Touch Sirolimus Coated Balloon&#xD;
      (SCB) compared to one of the gold standard treatment for native vessel disease&#xD;
      (everolimus-eluting stent, EES).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of TRANSFORM II study is to observe and evaluate the efficacy of Magic Touch SCB&#xD;
      compared to the gold standard treatment for native vessel disease, namely new-generation&#xD;
      everolimus-eluting Drug Eluting Stent (DES). Given the inherent and recognized limitations of&#xD;
      stents in native vessels with diameter &lt;3 mm, only patients with coronary vessels up to 3 mm&#xD;
      of diameter (by visual estimation) will be enrolled in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of target Lesion Failure (TLF) at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>Non-inferiority of Magic Touch SCB compared to everolimus-eluting DES (EES) in terms of target lesion failure (TLF), a composite clinical endpoint, at 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of NACEs</measure>
    <time_frame>12 Months</time_frame>
    <description>Verify the superiority of the study device in terms of net adverse clinical events (NACE), a composite endpoint including all-cause death, myocardial infarction (MI), ischemic stroke, and major bleedings following the Bleeding Academic Research Consortium (BARC) types 3 or 5 definition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The occurrence of cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause;</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The occurrence of death of any cause;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q-wave MI</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The occurrence of Q-wave MI;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The occurrence of any MI;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The occurrence of TLR;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The occurrence of target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>The occurrence of bleedings following the BARC classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1325</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Everolimus Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Magic Touch Sirolimus Coated Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus Eluting Stent</intervention_name>
    <description>Patients assigned to this Arm will have an EES implanted after pre-dilatation, the angiography will be conducted as standard of care</description>
    <arm_group_label>Everolimus Eluting Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus Coated Balloon</intervention_name>
    <description>Patients assigned to this Arm will be treated with Magic Touch Drug Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care</description>
    <arm_group_label>Magic Touch Sirolimus Coated Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;18 years;&#xD;
&#xD;
          -  all patients with a clinical indication to Percutaneous Coronary Intervention (PCI)&#xD;
             (stable coronary artery disease or acute coronary syndromes);&#xD;
&#xD;
          -  native coronary artery lesion in a vessel with diameter &gt;2.0 mm and ≦3.0 mm at visual&#xD;
             estimation;&#xD;
&#xD;
          -  maximum lesion length: 40 mm.&#xD;
&#xD;
          -  informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with known (and untreatable) hypersensitivity or contraindication to aspirin,&#xD;
             heparin, clopidogrel, prasugrel, ticagrelor, sirolimus or contrast media, which cannot&#xD;
             be adequately pre-medicated;&#xD;
&#xD;
          -  patients participating in another clinical study;&#xD;
&#xD;
          -  subject is a woman who is pregnant or nursing (pregnancy test, either urine or blood&#xD;
             test must be performed within 7 days prior to the index procedure in woman of&#xD;
             child-bearing potential, and must not commit to initiating a pregnancy for 12 weeks&#xD;
             after implantation, using effective contraception);&#xD;
&#xD;
          -  creatinine clearance &lt;30 ml/min;&#xD;
&#xD;
          -  left ventricular ejection fraction &lt;30%;&#xD;
&#xD;
          -  life expectancy &lt;12 months;&#xD;
&#xD;
          -  ST-elevation myocardial infarction in the previous 48 hours;&#xD;
&#xD;
          -  visible thrombus at lesion site;&#xD;
&#xD;
          -  culprit lesion stenosis &gt;99% and/or Thrombolysis In Myocardial Infarction (TIMI) flow&#xD;
             &lt;2;&#xD;
&#xD;
          -  target lesion/vessel with any of the following characteristics:&#xD;
&#xD;
          -  concomitant PCI at the same vessel with any device (vessels are considered: left&#xD;
             anterior descending, circumflex or right coronary artery);&#xD;
&#xD;
          -  pre-dilatation of the target lesion not performed or not successful (residual stenosis&#xD;
             &gt;30%);&#xD;
&#xD;
          -  severe calcification of the target vessel, at lesion site but also proximally;&#xD;
&#xD;
          -  highly tortuous vessel which could impair device delivery to the lesion site following&#xD;
             Investigator's judgement;&#xD;
&#xD;
          -  previous stent implantation at target vessel (left anterior descending artery;&#xD;
             circumflex artery; right coronary artery);&#xD;
&#xD;
          -  bifurcation lesion where side branch treatment is anticipated;&#xD;
&#xD;
          -  left main stem stenosis &gt;50%;&#xD;
&#xD;
          -  target lesion is in left main stem&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernardo Cortese, Dr.</last_name>
    <phone>+39 348 1123968</phone>
    <email>bcortese@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014 Jan;11(1):13-23. doi: 10.1038/nrcardio.2013.165. Epub 2013 Nov 5. Review.</citation>
    <PMID>24189405</PMID>
  </reference>
  <reference>
    <citation>Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010 Aug;96(16):1291-6. doi: 10.1136/hrt.2010.195057.</citation>
    <PMID>20659948</PMID>
  </reference>
  <reference>
    <citation>Cortese B. The PICCOLETO study and beyond. EuroIntervention. 2011 May;7 Suppl K:K53-6. doi: 10.4244/EIJV7SKA9.</citation>
    <PMID>22027728</PMID>
  </reference>
  <reference>
    <citation>Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P, Sgueglia GA, Buffoli F, Tamburino C, Varbella F, Menozzi A. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. 2012 Dec 18;60(24):2473-80. doi: 10.1016/j.jacc.2012.09.020. Epub 2012 Nov 14. Erratum in: J Am Coll Cardiol. 2013 Apr 16;61(15):1660.</citation>
    <PMID>23158530</PMID>
  </reference>
  <reference>
    <citation>Cortese B, Sgueglia GA, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A; Italian Society of Interventional Cardiology (SICI-GISE). [SICI-GISE position paper on drug-coated balloon use in the coronary district]. G Ital Cardiol (Rome). 2013 Oct;14(10):681-9. doi: 10.1714/1335.14836. Italian.</citation>
    <PMID>24121894</PMID>
  </reference>
  <reference>
    <citation>Cortese B, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A, Silva PL, Sgueglia GA; Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv. 2014 Feb 15;83(3):427-35. doi: 10.1002/ccd.25149. Epub 2013 Sep 23. Review.</citation>
    <PMID>23934956</PMID>
  </reference>
  <reference>
    <citation>Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, Schreiber M, Mahfoud F, Linke A, Stephan FP, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018 Sep 8;392(10150):849-856. doi: 10.1016/S0140-6736(18)31719-7. Epub 2018 Aug 28.</citation>
    <PMID>30170854</PMID>
  </reference>
  <reference>
    <citation>B. Cortese et Al., PICCOLETO II study, JACC Interventions, 2020, in press</citation>
  </reference>
  <reference>
    <citation>Scheller B, Vukadinovic D, Jeger R, Rissanen TT, Scholz SS, Byrne R, Kleber FX, Latib A, Clever YP, Ewen S, Böhm M, Yang Y, Lansky A, Mahfoud F. Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. J Am Coll Cardiol. 2020 Mar 10;75(9):1017-1028. doi: 10.1016/j.jacc.2019.11.065.</citation>
    <PMID>32138961</PMID>
  </reference>
  <reference>
    <citation>Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, Christians U, Kharlamov A, Doshi M, Sojitra P, van Beusekom HM, Serruys PW. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013 May 20;9(1):148-56. doi: 10.4244/EIJV9I1A21.</citation>
    <PMID>23685303</PMID>
  </reference>
  <reference>
    <citation>Cortese B, di Palma G, Latini RA, Elwany M, Orrego PS, Seregni RG. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry. Cardiovasc Revasc Med. 2017 Oct - Nov;18(7):487-491. doi: 10.1016/j.carrev.2017.03.025. Epub 2017 Mar 25.</citation>
    <PMID>28365415</PMID>
  </reference>
  <reference>
    <citation>Cortese B, Pellegrini D, Latini RA, Di Palma G, Perotto A, Orrego PS. Angiographic performance of a novel sirolimus-coated balloon in native coronary lesions: the FAtebenefratelli SIrolimus COated NATIVES prospective registry. J Cardiovasc Med (Hagerstown). 2019 Jul;20(7):471-476. doi: 10.2459/JCM.0000000000000806.</citation>
    <PMID>30994510</PMID>
  </reference>
  <reference>
    <citation>Cortese B, Testa L, Di Palma G, Heang TM, Bossi I, Nuruddin AA, Ielasi A, Tespili M, Perez IS, Milazzo D, Benincasa S, Latib A, Cacucci M, Caiazzo G, Seresini G, Tomai F, Ocaranza R, Torres A, Perotto A, Bedogni F, Colombo A. Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. J Cardiovasc Med (Hagerstown). 2021 Feb 1;22(2):94-100. doi: 10.2459/JCM.0000000000001070.</citation>
    <PMID>32740442</PMID>
  </reference>
  <reference>
    <citation>Kleber FX, Schulz A, Waliszewski M, Hauschild T, Böhm M, Dietz U, Cremers B, Scheller B, Clever YP. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015 Mar;104(3):217-25. doi: 10.1007/s00392-014-0775-2. Epub 2014 Oct 28.</citation>
    <PMID>25349065</PMID>
  </reference>
  <reference>
    <citation>Cortese B, Silva Orrego P, Agostoni P, Buccheri D, Piraino D, Andolina G, Seregni RG. Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection. JACC Cardiovasc Interv. 2015 Dec 28;8(15):2003-2009. doi: 10.1016/j.jcin.2015.08.029. Epub 2015 Nov 25.</citation>
    <PMID>26627997</PMID>
  </reference>
  <reference>
    <citation>Onishi T, Onishi Y, Kobayashi I, Sato Y. Late lumen enlargement after drug-coated balloon angioplasty for de novo coronary artery disease. Cardiovasc Interv Ther. 2021 Jul;36(3):311-318. doi: 10.1007/s12928-020-00690-2. Epub 2020 Jul 9. Erratum in: Cardiovasc Interv Ther. 2020 Sep 17;:.</citation>
    <PMID>32647991</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DCB</keyword>
  <keyword>EES</keyword>
  <keyword>Optical Coherence Tomography (OCT)</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Everolimus</keyword>
  <keyword>TLF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

